Events

Recall of Device Recall AdaptivCRT (aCRT)

According to U.S. Food and Drug Administration, this recall involved a device in United States that was produced by Medtronic Inc., Cardiac Rhythm and Heart Failure.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    75943
  • Event Risk Class
    Class 2
  • Event Number
    Z-0962-2017
  • Event Initiated Date
    2016-12-09
  • Event Status
    Open, Classified
  • Event Country
    United States
  • Event Source
    USFDA
  • Event Source URL
    https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=151797
  • Notes / Alerts
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • Extra notes in the data
    Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) - Product Code NIK
  • Reason
    During internal testing conducted as part of next generation product development, it was discovered that the adaptivcrt (acrt) feature of amplia mri and claria mri crt -d devices may appear to be enabled when it is not active.
  • Action
    Consignees were hand delivered beginning on 12/9/2016 a Medtronic "Urgent Medical Device Correction" letter dated December 2016. The letter was addressed to "Dear Physician". The letter described the issue and the product involved in the recall. The letter informed consignees that a software update is being developed to address the issue and it will also address other issue not covered in this recall. The letter also included Appendix A which listed Patient Management Recommendations (Until the software update has been approved and the device models listed in Table A receive the update, follow the programming recommendations found in Appendix A. These recommendations also apply to any new device implants). Additionally, two other "Urgent Medical Device Correction" letters were hand delivered to the consignees, "Principal Investigator Contact Record" and a supplement to the advisory notification. For questions contact your local Medtronic Representative or Medtronic Technical Services at 800-723-4636.

Device

Device Recall AdaptivCRT (aCRT)
  • Model / Serial
  • Product Classification
    Cardiovascular Devices
  • Device Class
    3
  • Implanted device?
    Yes
  • Distribution
    US: All states in USA including DC & PR. OUS: Australia, Finland, Japan, Saudi Arabia, Austria, France, Korea,Singapore, Bangladesh, Germany, Luxembourg, South Africa, Belgium, Greece, Malaysia, Spain, Brunei Darussalam, Guadeloupe, Netherlands, Sweden, Cayman Islands, Hong Kong, New Zealand, Switzerland, Chile, India, Norway, Thailand, Cyprus, Iran, Poland, Turkey, Denmark, Ireland, Portugal, United Arab Emirates, Dominican Republic, Italy, Reunion, United Kingdom.
  • Product Description
    Amplia MRI" CRT -D SureScan", || Amplia MRI" Quad CRT -D SureScan", || Claria MRI" CRT -D SureScan", || Claria MRI" Quad CRT -D SureScan. implantable medical devices that automatically detect and treat episodes of ventricular fibrillation, ventricular tachycardia, fast ventricular tachycardia, and bradyarrhythmia.
  • Manufacturer
    Medtronic Inc., Cardiac Rhythm and Heart Failure

Manufacturer

Medtronic Inc., Cardiac Rhythm and Heart Failure
  • Manufacturer Address
    Medtronic Inc., Cardiac Rhythm and Heart Failure, 8200 Coral Sea St NE, Mounds View MN 55112-4391
  • Manufacturer Parent Company (2017)
    Medtronic plc
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    USFDA